Roche reported that the EMEA’s Committee for Medicinal Products for Human Use supported broadening Avastin’s (bevacizumab) label for the first-line treatment of patients with metastatic breast cancer. The recommendation was made to allow the drug’s use in combination with sanofi-aventis’ Taxotere (docetaxel) for these patients.

[ad]

Avastin is already approved in Europe, in combination with paclitaxel, as a first-line treatment for patients with metastatic breast cancer. The drugmaker said the positive opinion for the combination of Avastin plus Taxotere was based on Phase III data from the 736-patient AVADO study, which showed that those given Avastin plus sanofi-aventis’ chemotherapy drug experienced increased progression-free survival, compared with Taxotere alone.

Avastin is also cleared for use in Europe to treat advanced stages of colorectal, kidney, and non-small-cell lung cancers.

Source: FirstWord

Popularity: 4% [?]